Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 2/20 | 0.42 |
| ▸ | RXRA | P19793 | 2/20 | 0.42 |
| ▸ | RXRB | P28702 | 2/20 | 0.42 |
| ▸ | RXRG | P48443 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6766448 | 0.83 | NAMPT (0.61) | SMN1; SMN2NPC1RAB9AKMT2AMEN1 | |
| SCHEMBL6766906 | 0.81 | NPC1 (0.46) | SMN1; SMN2NPC1RAB9APOLBHPGD | |
| SCHEMBL10636593 | 0.79 | NPC1 (0.71) | SMN1; SMN2NPC1RAB9APOLBHPGD | |
| SCHEMBL7399657 | 0.78 | NPC1 (0.69) | SMN1; SMN2NPC1RAB9APOLBHPGD | |
| SCHEMBL6765613 | 0.77 | MEN1 (0.52) | SMN1; SMN2NPC1RAB9APOLBPLA2G4B | |
| SCHEMBL23329441 | 0.76 | CA1 (0.67) | HPGDCA1CA2CA7CA9 | |
| SCHEMBL29373515 | 0.76 | CA1 (0.67) | HPGDCA1CA2CA7CA9 | |
| SCHEMBL6754368 | 0.75 | NPC1 (0.44) | SMN1; SMN2NPC1RAB9APOLBPLA2G4B | |
| SCHEMBL16689961 | 0.74 | KMT2A (0.67) | SMN1; SMN2NPC1RAB9APOLBHPGD | |
| SCHEMBL6754372 | 0.74 | MAPK1 (0.43) | SMN1; SMN2NPC1RAB9APOLBPLA2G4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040038973-A1 | Treating osteoarthritis or rheumatoid arthritis | NAHRA JOE (US) | 2004-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038973-A1 | Treating osteoarthritis or rheumatoid arthritis | MMP13, MMP11, MMP9 | SMN1; SMN2 984/4885NPC1 1199/4885RAB9A 425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.